The altered MALT1-A20-NF-κB pathway may contribute to the pathogenesis of B-ALL, and this pathway may be considered a potentially attractive target for the development of B-ALL therapeutics. The gene discussed is TNFAIP3; the disease is acute lymphoblastic leukemia.